Harrell C C, Kline S S
Ann Arbor Veterans Affairs Medical Center, MI, USA.
Ann Pharmacother. 1995 Dec;29(12):1228-32. doi: 10.1177/106002809502901207.
To report 6 patients taking oral vitamin K1 (phytonadione) to reduce warfarin's activity.
Six patient cases are summarized in which oral vitamin K1 was used to reduce the international normalized ratio (INR) in patients at risk of bleeding.
The use of oral vitamin K1 to antagonize warfarin's effects is discussed, as well as the benefits of oral vitamin K1 administration and the disadvantages of parenteral vitamin K1 administration. In addition, an extensive literature review of the discovery and clinical development of warfarin and vitamin K1 is described.
In patients receiving warfarin therapy who have an increased INR and are at risk of bleeding, oral vitamin K1 therapy may be safer, less painful, and more cost-effective than the traditional parenteral route of administration.
报告6例服用口服维生素K1（植物甲萘醌）以降低华法林活性的患者。
总结了6例患者的情况，其中口服维生素K1用于降低有出血风险患者的国际标准化比值（INR）。
讨论了使用口服维生素K1拮抗华法林作用的情况，以及口服维生素K1给药的益处和胃肠外给予维生素K1的弊端。此外，还描述了对华法林和维生素K1的发现及临床开发的广泛文献综述。
在接受华法林治疗且INR升高并有出血风险的患者中，口服维生素K1治疗可能比传统的胃肠外给药途径更安全、痛苦更小且更具成本效益。
